General hospital psychiatry · 2025
Impact of virtual reality-based rehabilitation on poststroke depression: A systematic review and meta-analysis.
СтатьяМетаанализСистематический обзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wei Ying, Tian Hao, Ma Cungen, Song Lijuan
Аннотация
BACKGROUND: Depression is the most common neuropsychiatric sequela of stroke, negatively affecting functional recovery and quality of life. Although virtual reality-based rehabilitation (VRBR) is an effective intervention in stroke rehabilitation, its efficacy in treating poststroke depression (PSD) remains unclear.
OBJECTIVES: To evaluate the treatment effect of VRBR on PSD.
DATA SOURCES AND METHODS: Six medical databases were systematically searched from inception to May 31, 2024, with an update on October 5, 2024. Potentially eligible studies were screened against the inclusion and exclusion criteria. Review Manager 5.4 and Stata 14.0 were used to conduct statistical analysis.
RESULTS: Twelve studies published between 2015 and 2024 were included. The pooled results revealed that VRBR significantly reduced depression scores among poststroke patients [SMD = -0.56, 95 % CI (-0.90,-0.23), P = 0.001]. Subgroup analyses suggested numerically greater improvements in patients with a mean age < 60 years and those receiving ≥20 intervention sessions, though between-subgroup differences were not statistically significant.
CONCLUSION: VRBR may be a promising therapy for PSD. However, methodologically rigorous studies are needed to further confirm its efficacy and safety.
TRIAL REGISTRATION: PROSPERO, CRD42024550019.
OBJECTIVES: To evaluate the treatment effect of VRBR on PSD.
DATA SOURCES AND METHODS: Six medical databases were systematically searched from inception to May 31, 2024, with an update on October 5, 2024. Potentially eligible studies were screened against the inclusion and exclusion criteria. Review Manager 5.4 and Stata 14.0 were used to conduct statistical analysis.
RESULTS: Twelve studies published between 2015 and 2024 were included. The pooled results revealed that VRBR significantly reduced depression scores among poststroke patients [SMD = -0.56, 95 % CI (-0.90,-0.23), P = 0.001]. Subgroup analyses suggested numerically greater improvements in patients with a mean age < 60 years and those receiving ≥20 intervention sessions, though between-subgroup differences were not statistically significant.
CONCLUSION: VRBR may be a promising therapy for PSD. However, methodologically rigorous studies are needed to further confirm its efficacy and safety.
TRIAL REGISTRATION: PROSPERO, CRD42024550019.